News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Reports Second Quarter 2020 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
STAMFORD, Conn. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today
View HTML
Toggle Summary Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
STAMFORD, Conn. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
STAMFORD, Conn. , June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
- Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of  >4-point improvement responder analysis - - Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn.
View HTML
Toggle Summary Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
STAMFORD, Conn. , May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2020 Financial Results
Conference call today at 4:30 p.m. ET STAMFORD, Conn. , May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference
STAMFORD, Conn. , May 07, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
STAMFORD, Conn. , May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the
View HTML
Toggle Summary Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) - Statistically significant improvement in key secondary endpoint of proportion of patients with four point or
View HTML